YOLFTbeta
Shenzhen Weiguang Biological Products Co Ltd

Shenzhen Weiguang Biological Products Co Ltd

002880 · SHE · Healthcare / Biotechnology

19.30CNY-0.52 (-2.62%)

Price History

Full chart

Market Stats

Previous Close19.82
Open19.90
Day Range19.30 – 19.93
52-Week Range18.57 – 33.53
Volume1.20M
Market Cap5.05B
P/E (TTM)27.49
Forward P/E0.00
EPS0.81
Dividend Yield0.92%
Beta0.29
50-Day Avg21.07
200-Day Avg24.87

About

Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Caiping Guo
  • Employees901
  • HeadquartersNo. 3402, Guangqiao Avenue, Shenzhen, China, 518107, China
  • Websitehttps://www.szwg.com

Leadership

  • Ms. Caiping GuoGM & Director · b. 1971
  • Mr. Guan Qun ChenCFO & Director · b. 1977
  • Mr. Wenjie XieDeputy GM & Employee Director · b. 1976
  • Ms. Xuefen LiuSecretary of the Board of Directors · b. 1978
  • Kui HuangAccounting Supervisor

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue300.07M355.21M452.77M500.94M566.14M623.39M687.95M821.47M904.56M907.43M667.93M1.05B1.20B1.27B
Growth (%)-+18.38%+27.47%+10.64%+13.01%+10.11%+10.36%+19.41%+10.12%+0.32%-26.39%+56.98%+14.75%+5.28%
Cost of Revenue155.00M179.89M257.86M268.01M297.84M347.17M414.33M506.13M568.22M536.52M427.02M615.26M699.32M768.05M
Gross Profit145.07M175.32M194.91M232.94M268.30M276.21M273.62M315.34M336.35M370.91M240.91M433.24M503.87M498.61M
Gross Margin48.35%49.36%43.05%46.50%47.39%44.31%39.77%38.39%37.18%40.87%36.07%41.32%41.88%39.36%
Operating Expense58.41M62.59M83.80M93.85M99.74M97.38M91.62M116.19M115.70M129.17M102.74M185.94M207.24M174.61M
Operating Income86.66M112.73M111.11M139.09M168.56M178.84M182.00M199.14M220.64M241.74M138.17M247.31M296.62M324.00M
Operating Margin28.88%31.74%24.54%27.77%29.77%28.69%26.46%24.24%24.39%26.64%20.69%23.59%24.65%25.58%
EBITDA98.92M133.89M181.86M210.49M237.61M232.47M227.55M238.64M265.95M298.68M203.58M347.03M435.27M458.41M
EBITDA Margin32.97%37.69%40.17%42.02%41.97%37.29%33.08%29.05%29.40%32.91%30.48%33.10%36.18%36.19%
Net Income71.45M88.88M100.54M124.86M153.23M154.75M156.64M171.34M190.40M205.44M117.52M218.65M253.52M246.32M
Net Income Margin23.81%25.02%22.21%24.92%27.07%24.82%22.77%20.86%21.05%22.64%17.59%20.85%21.07%19.45%
R&D11.94M15.47M13.78M19.78M24.77M25.63M23.70M40.16M45.10M47.59M35.87M63.62M49.05M46.02M
R&D as % of Total Revenue3.98%4.35%3.04%3.95%4.38%4.11%3.45%4.89%4.99%5.24%5.37%6.07%4.08%3.63%
Interest Expense--25.01M24.77M18.06M10.09M3.90M554.15K1.19M3.06M3.02M15.31M22.87M20.89M
Interest Expense % of Total Revenue--5.52%4.95%3.19%1.62%0.57%0.07%0.13%0.34%0.45%1.46%1.90%1.65%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets665.63M712.79M769.59M855.97M909.88M1.37B1.46B1.59B1.84B2.00B2.58B2.88B3.30B3.74B
Total Liabilities530.63M488.91M460.73M462.25M403.44M171.52M153.53M136.64M212.36M215.23M708.20M831.14M1.05B1.29B
Total Equity135.00M223.88M308.86M393.71M506.44M1.20B1.31B1.45B1.60B1.77B1.84B2.01B2.21B2.41B
Cash139.94M70.38M113.54M119.23M61.91M338.97M260.32M304.61M471.47M332.10M294.59M252.30M274.76M369.81M
Total Debt295.00M379.38M355.07M363.38M294.82M70.00M29.00M-82.00M43.42M547.02M499.79M669.48M-
Net Debt155.06M309.00M241.54M244.15M232.92M-268.97M-231.32M-304.61M-389.47M-288.68M252.44M247.49M394.72M406.41M

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow115.88M20.93M134.17M150.09M126.41M28.61M99.54M185.70M303.96M246.89M1.20M397.94M177.77M263.18M
Investing Cash Flow-131.34M-49.20M-31.19M-81.93M-55.30M-60.56M-79.86M-100.64M-202.59M-290.08M-487.26M-352.17M-238.20M-
Financing Cash Flow44.59M-41.29M-59.82M-80.47M-110.42M309.01M-98.33M-40.34M65.53M-96.18M447.90M-88.18M83.72M-
Capital Expenditure172.95M56.93M38.37M85.86M59.91M61.36M84.51M77.79M189.19M240.83M327.37M328.85M255.50M169.69M
Free Cash Flow-57.07M-36.00M95.79M64.23M66.49M-32.75M15.03M107.91M114.76M6.06M-326.17M69.08M-77.73M93.49M
Dividends Paid110.41M125.67M37.32M69.43M58.80M94.02M57.33M32.54M35.68M40.50M45.36M65.60M65.88M65.73M
FCF to OCF-49.25%-172.01%71.40%42.79%52.60%-114.44%15.10%58.11%37.76%2.45%-27202.88%17.36%-43.73%35.52%
Dividend Paid to FCF-193.48%-349.08%38.96%108.10%88.43%-287.11%381.50%30.15%31.09%668.34%-13.91%94.96%-84.75%70.30%

Earnings

Report DateAug 30, 2017Oct 19, 2017Feb 26, 2018Apr 21, 2018Jul 27, 2018Oct 23, 2018Dec 31, 2018Apr 24, 2019Aug 20, 2019Oct 24, 2019Mar 6, 2020Apr 24, 2020Aug 21, 2020Oct 27, 2020Dec 31, 2020Apr 28, 2021Aug 19, 2021Oct 26, 2021Dec 31, 2021Apr 14, 2022Aug 29, 2022Oct 30, 2022Dec 31, 2022Apr 25, 2023Aug 24, 2023Oct 25, 2023Feb 22, 2024Apr 25, 2024Aug 27, 2024Sep 30, 2024Dec 31, 2024Apr 22, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------
EPS Actual0.180.140.210.110.200.170.210.120.190.170.270.200.280.190.310.170.190.300.300.110.100.110.200.200.240.220.300.210.280.320.310.190.280.220.390.140.06
Surprise-------------------------------------
TimingAfter-hoursPre-marketPre-marketAfter-hours-Pre-market-Pre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours-Pre-marketAfter-hoursPre-market-Pre-marketPre-marketAfter-hours-Pre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market--Pre-market-----

Key Statistics & Ratios

Market Cap5.05B
Enterprise Value5.70B
Trailing P/E27.49
Forward P/E0.00
Price / Sales4.22
Price / Book2.06
EPS0.81
Book Value10.63
Revenue (TTM)1.20B
Gross Profit (TTM)420.53M
EBITDA375.50M
Profit Margin15.29%
Operating Margin9.76%
Return on Equity7.70%
Return on Assets3.93%
Shares Outstanding226.80M
Shares Float56.45M
Beta0.29
Dividend Yield0.92%
Dividend Rate0.20
Payout Ratio24.78%

Dividends

20261×
0.20May 27, 2026
20251×
0.20Jul 17, 2025
20241×
0.20Jul 12, 2024
20231×
0.20Oct 31, 2023
20221×
0.20Jul 8, 2022
20211×
0.18Jun 16, 2021
20201×
0.15Apr 29, 2020
20191×
0.14Jun 28, 2019
20181×
0.24May 22, 2018

Stock Splits

  • Jun 16, 20211.4:1
  • Apr 29, 20201.5:1